Vietnamese battery startup Alterno has announced raising $1.5 million in its latest funding round while Singapore-based healthcare firm Auristone secures $4 million to boost its flagship molecular profiling test.
Singapore’s Auristone secures $4m in seed funding
Auristone, a Singapore-based epigenomic research and innovation company, has raised $4 million in its seed funding round, per a company statement.
The round was anchored by Southeast Asia-focused tech investor Elev8.vc and backed by SEEDS Capital, the investment arm of Enterprise Singapore. Existing investor Genedant also made a follow-on investment.
The company said it will use the fresh capital to enhance its capabilities through clinical collaborations and to drive market adoption of EPI-CALL by working with regional genomic companies.
EPI-CALL, Auristone’s flagship molecular profiling test, is designed to help doctors and patients navigate the complexities of therapy selection for late-stage cancer patients.
Using epigenomics, Auristone can predict an individual patient’s likelihood of response to different treatment options and help doctors determine the most-suited treatment plans for their patients.
Vietnam’s Alterno raises $1.5m in latest funding round
Alterno, a Vietnamese startup that provides thermal energy storage solutions using sand battery technology, has announced raising $1.5 million in an oversubscribed funding round.
The round was co-anchored by Singapore-based early-stage investor The Radical Fund and Vietnamese venture capital firm Touchstone Partners. Antler, Impact Square, and Glocalink also participated in the round.
Alterno provides thermal energy storage solutions tailored for agricultural applications across drying, warming, or heating needs. Its patented technology comprises insulated sand with heat-conducting tubes.
Previously, Alterno received grants from international foundations, including $200,000 from the Temasek Foundation, $350,000 from P4G, and $40,000 from the Japan International Cooperation Agency.
